Clinical Research Directory
Browse clinical research sites, groups, and studies.
Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia
Sponsor: Peking Union Medical College Hospital
Summary
Current retrospective studies have demonstrated that achieving deep remission following treatment for Waldenström's macroglobulinemia (WM) correlates with prolonged survival. While the bendamustine-rituximab (BR) regimen or single-agent zanubrutinib are currently recommended as first-line therapies, neither achieves optimal deep remission. Additionally, prolonged zanubrutinib monotherapy may lead to cumulative adverse effects. Therefore, this study aims to evaluate the efficacy and safety of the bendamustine-rituximab-zanubrutinib combination regimen as a first-line treatment option for MYD88-mutated WM patients.
Official title: A Multicenter Study on the First-line Treatment of Waldenström's Macroglobulinemia With Zanubrutinib in Combination With Rituximab and Bendamustine
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
104
Start Date
2025-05-01
Completion Date
2029-04-30
Last Updated
2025-04-30
Healthy Volunteers
No
Conditions
Interventions
Zanubrutinib
zanubrutinib 160mg po bid d1-28
Bendamustine + Rituximab
bendamustine 70-90mg/m2 ivgtt d1-2, rituximab 375mg/m2 ivgtt d1
Locations (1)
Peking Union Medical College Hospital
Beijing, China